146 related articles for article (PubMed ID: 32957757)
21. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.
Senoo K; Lip GY
Int J Cardiol; 2016 Oct; 221():379-82. PubMed ID: 27409565
[TBL] [Abstract][Full Text] [Related]
22. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
[TBL] [Abstract][Full Text] [Related]
23. Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project.
Guo YT; Zhang Y; Shi XM; Shan ZL; Wang CJ; Wang YT; Chen YD; Lip GY
Sci Rep; 2016 Aug; 6():31755. PubMed ID: 27557876
[TBL] [Abstract][Full Text] [Related]
24. Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study.
Zhou W; Wang T; Zhu LJ; Wen MH; Hu LH; Huang X; You CJ; Li JX; Wu YQ; Wu QH; Bao HH; Cheng XS
Chin Med J (Engl); 2019 Sep; 132(18):2150-2156. PubMed ID: 31490268
[TBL] [Abstract][Full Text] [Related]
25. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the CHA
Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
[TBL] [Abstract][Full Text] [Related]
27. Risk scores for major bleeding from direct oral anticoagulants: comparing predictive performance in patients with atrial fibrillation.
Campos-Staffico AM; Jacoby JP; Dorsch MP; Limdi NA; Barnes GD; Luzum JA
Res Pract Thromb Haemost; 2024 Jan; 8(1):102285. PubMed ID: 38292348
[TBL] [Abstract][Full Text] [Related]
28. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
[TBL] [Abstract][Full Text] [Related]
29. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation.
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
Sci Rep; 2017 Sep; 7(1):12066. PubMed ID: 28935868
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: A network meta-analysis.
Chang G; Xie Q; Ma L; Hu K; Zhang Z; Mu G; Cui Y
J Thromb Haemost; 2020 Apr; 18(4):791-801. PubMed ID: 31782613
[TBL] [Abstract][Full Text] [Related]
31. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Tepper PG; Mardekian J; Masseria C; Phatak H; Kamble S; Abdulsattar Y; Petkun W; Lip GYH
PLoS One; 2018; 13(11):e0205989. PubMed ID: 30383768
[TBL] [Abstract][Full Text] [Related]
32. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Red Blood Cell Distribution Width on Bleeding Events in Nonvalvular Atrial Fibrillation Patients Taking Dabigatran (110 mg b.i.d.) after Catheter Ablation.
Zhang Q; Qin Y; Zhao DS; Zhao HP; Zhou L
Cardiology; 2017; 136(4):215-221. PubMed ID: 27802430
[TBL] [Abstract][Full Text] [Related]
34. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
35. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
Chan YH; Yeh YH; See LC; Wang CL; Chang SH; Lee HF; Wu LS; Tu HT; Kuo CT
J Am Coll Cardiol; 2016 Nov; 68(21):2272-2283. PubMed ID: 27884245
[TBL] [Abstract][Full Text] [Related]
36. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project.
Lip GY; Banerjee A; Lagrenade I; Lane DA; Taillandier S; Fauchier L
Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):941-8. PubMed ID: 22923275
[TBL] [Abstract][Full Text] [Related]
37. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Owada S; Tomita H; Kinjo T; Ishida Y; Itoh T; Sasaki K; Horiuchi D; Kimura M; Sasaki S; Okumura K
Thromb Res; 2015 Jan; 135(1):62-7. PubMed ID: 25466835
[TBL] [Abstract][Full Text] [Related]
38. Association Between the Change in Total Bilirubin and Risk of Bleeding Among Patients With Nonvalvular Atrial Fibrillation Taking Dabigatran.
Xiong Y; Hu L; Zhou W; Li M; Wang T; Huang X; Bao H; Cheng X
Clin Appl Thromb Hemost; 2020; 26():1076029620910808. PubMed ID: 32343610
[TBL] [Abstract][Full Text] [Related]
39. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
40. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Lip GYH; Mauri L; Montalescot G; Ozkor M; Vardas P; Steg PG; Bhatt DL; Hohnloser SH; Miede C; Nordaby M; Brueckmann M; Kreuzer J; Kimura T; Oldgren J; Ten Berg JM; Cannon CP
Am Heart J; 2019 Jun; 212():13-22. PubMed ID: 30928824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
